Regeneron Pharmaceuticals, Inc. (REGN)
828.72
-5.32
(-0.64%)
USD |
NASDAQ |
Aug 24, 16:00
834.55
+5.83
(+0.70%)
After-Hours: 20:00
Regeneron Pharmaceuticals Gross Profit Margin (Quarterly) : 83.68% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 83.68% |
| March 31, 2026 | 78.02% |
| December 31, 2025 | 81.22% |
| September 30, 2025 | 82.47% |
| June 30, 2025 | 81.90% |
| March 31, 2025 | 80.48% |
| December 31, 2024 | 81.75% |
| September 30, 2024 | 83.53% |
| June 30, 2024 | 83.06% |
| March 31, 2024 | 82.58% |
| December 31, 2023 | 81.68% |
| September 30, 2023 | 83.89% |
| June 30, 2023 | 83.91% |
| March 31, 2023 | 82.39% |
| December 31, 2022 | 85.15% |
| September 30, 2022 | 86.02% |
| June 30, 2022 | 87.00% |
| March 31, 2022 | 83.84% |
| December 31, 2021 | 78.65% |
| September 30, 2021 | 84.75% |
| June 30, 2021 | 85.12% |
| March 31, 2021 | 85.15% |
| December 31, 2020 | 82.88% |
| September 30, 2020 | 85.47% |
| June 30, 2020 | 82.87% |
| Date | Value |
|---|---|
| March 31, 2020 | 85.05% |
| December 31, 2019 | 85.19% |
| September 30, 2019 | 84.03% |
| June 30, 2019 | 87.46% |
| March 31, 2019 | 83.75% |
| December 31, 2018 | 91.70% |
| September 30, 2018 | 91.23% |
| June 30, 2018 | 92.21% |
| March 31, 2018 | 89.99% |
| December 31, 2017 | 91.14% |
| September 30, 2017 | 90.54% |
| June 30, 2017 | 90.61% |
| March 31, 2017 | 90.73% |
| December 31, 2016 | 91.56% |
| September 30, 2016 | 94.09% |
| June 30, 2016 | 92.24% |
| March 31, 2016 | 88.78% |
| December 31, 2015 | 87.82% |
| September 30, 2015 | 88.59% |
| June 30, 2015 | 89.57% |
| March 31, 2015 | 88.50% |
| December 31, 2014 | 90.83% |
| September 30, 2014 | 90.41% |
| June 30, 2014 | 91.08% |
| March 31, 2014 | 91.19% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Gilead Sciences, Inc. | 79.81% |
| AbbVie, Inc. | 74.71% |
| Vertex Pharmaceuticals, Inc. | 85.37% |
| Amgen, Inc. | 72.08% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 13.94% |
| Return on Assets | 10.74% |
| Return on Invested Capital | 12.80% |
| Profit Margin (Quarterly) | 30.23% |
| Operating Margin (Quarterly) | 33.11% |
| Return on Net Operating Assets | 27.85% |